Vanderbilt Ingram Cancer Center Archives
Lung cancer survival signal
Nov. 30, 2018—New research by Jonathan Lehman and Pierre Massion have identfied a bioimarker that suggests poor prognosis for small-cell lung cancer, as well as potential target for new therapies.
Grant enhances study of new chemotherapy targets
Oct. 19, 2018—Vanderbilt chemists have been awarded $7.2 million over the next five years from the National Cancer Institute to lead an initiative to better understand how a combination chemotherapy for breast cancer targets DNA.
Study tracks incidence, timing of immunotherapy-related deaths
Sep. 13, 2018—Researchers led by melanoma researcher Douglas Johnson have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.
My Southern Health: The symptoms of cholangiocarcinoma
Jul. 13, 2018—The signs of this rare bile-duct cancer typically go unnoticed at first. Here’s what to know.
Lung cancer patients and advocates visit VUMC research labs
Jun. 14, 2018—A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease.
Jagasia to succeed Neuss as VICC Chief Medical Officer
Jun. 12, 2018—After successfully leading Vanderbilt-Ingram Cancer Center (VICC) through years of growth in patient volumes and enhanced care options, Michael Neuss, MD, Chief Medical Officer of the VICC Clinical Enterprise, is retiring as CMO. Neuss will be succeeded by Madan Jagasia, MBBS, MSCI, MMHC, who has been named to the George and Beverley Rawlings Directorship and is section chief, Hematology and Stem Cell Transplant and director of the Outpatient Stem Cell Clinic.
VUMC and VICC lauded by CEO Roundtable on Cancer for employee support
May. 31, 2018—For the 10th year in a row Vanderbilt University Medical Center (VUMC) and Vanderbilt-Ingram Cancer Center (VICC) have been named a CEO Cancer Gold Standard employer by the
Berlin assumes new VICC leadership post
May. 29, 2018—Jordan Berlin, MD, has been named associate director of Clinical Investigation Strategy and Shared Resources at Vanderbilt-Ingram Cancer Center (VICC).
New method to thwart false positives in CT-lung cancer screening
May. 24, 2018—A team of investigators led by Fabien Maldonado, MD, associate professor of Medicine at Vanderbilt, and Tobias Peikert, MD, assistant professor of Medicine at Mayo Clinic, Rochester, Minnesota, has identified a new technology to address false positives in CT-based lung cancer screening. The study was published in the latest issue of PLOS One.
Park named to VICC breast cancer leadership position
May. 17, 2018— Internationally renowned breast cancer expert Ben Ho Park, MD, PhD, has been named co-leader of the Breast Cancer Research Program, director of Precision Oncology and associate director for Translational Research at Vanderbilt-Ingram Cancer Center. In his academic role, he will serve as professor of Medicine. Park, who will assume his new post Sept. 1,...
Grant bolsters kidney cancer immunotherapy research
May. 10, 2018—W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
VICC Scientific Retreat shines light on microbiome
May. 10, 2018—Two Vanderbilt students were honored for their stellar scientific research during the Vanderbilt-Ingram Cancer Center (VICC) Annual Scientific Retreat held May 3 at the Vanderbilt University Student Life Center.